Tirzepatide vs semaglutide: what the molecule difference means

Both drugs work by mimicking gut hormones, but they target different receptors—and the trial data shows that difference matters. Here's what the science says, and why neither drug is the right answer for everyone.

To understand why these drugs behave differently, it helps to know what the receptors they target actually do. GLP-1 (glucagon-like peptide-1) is a hormone released by the gut after eating. When a drug activates the GLP-1 receptor, it slows gastric emptying, reduces appetite signals in the brain, and promotes insulin release in proportion to blood sugar levels, working harder when blood sugar is high and easing off when it's normal. Semaglutide works entirely through this pathway. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone involved in energy balance and fat metabolism. Tirzepatide is engineered to activate both the GLP-1 and GIP receptors simultaneously. It is a single molecule designed to do this, not two separate drugs combined. What GIP receptor activation specifically contributes to tirzepatide's weight-loss effect is still being studied. The dual-receptor approach appears to add something meaningful to the overall effect, but the precise mechanism is not fully established. The drug works in trials; researchers are still working out exactly why.

Two large clinical trials established the weight-loss profiles of each drug.

STEP 1: semaglutide 2.4 mg (68 weeks)

Published in the New England Journal of Medicine, STEP 1 enrolled adults with obesity or overweight plus at least one weight-related condition. Participants received semaglutide 2.4 mg weekly alongside lifestyle counseling.

Mean weight loss: 14.9%

Achieved ≥5% weight loss: 86.4% of participants

Achieved ≥15% weight loss: 50.5% of participants

Side effects: Gastrointestinal events (nausea, diarrhea, vomiting) were the most common, typically mild to moderate, and most frequent during dose escalation

Other findings: Blood pressure, lipid levels, and blood sugar markers improved

SURMOUNT-1: tirzepatide 15 mg (72 weeks)

Also published in the New England Journal of Medicine, SURMOUNT-1 enrolled adults with obesity or overweight plus at least one weight-related condition, excluding those with type 2 diabetes. Participants received tirzepatide 15 mg weekly alongside lifestyle counseling.

Mean weight loss: 20.9%

Achieved ≥5% weight loss: 91% of participants

Achieved ≥20% weight loss: 57% of participants

Side effects: Gastrointestinal events followed a similar pattern, most common during dose escalation and typically mild to moderate

Other findings: Cardiometabolic measures, including blood pressure and lipid levels, also improved

A note on cross-trial comparisons

These numbers are real, but comparing them directly requires caution. STEP 1 and SURMOUNT-1 were separate trials with different participant populations, different durations (68 vs. 72 weeks), and different designs. Differences in results across two separate trials cannot be attributed solely to the drugs themselves. The numbers provide useful context, not a definitive verdict. That is precisely why a head-to-head trial was needed.

The most scientifically rigorous way to compare two drugs is to test them against each other in the same trial, with the same population, at the same time. SURMOUNT-5 was designed to do exactly that: directly compare tirzepatide 15 mg and semaglutide 2.4 mg in adults with obesity but without type 2 diabetes. Published in the New England Journal of Medicine, SURMOUNT-5 found that tirzepatide produced statistically significantly greater weight loss than semaglutide over 72 weeks. Participants on tirzepatide lost an average of 20.2% of body weight, compared with 13.7% for those on semaglutide, a relative difference of roughly 47%. A few caveats apply. The trial enrolled adults without type 2 diabetes, so these results may not apply equally to people with that condition. As with all trials, these are population averages; individual responses varied within both treatment groups. The trial also compared the maximum approved doses of each drug, so the findings do not speak to outcomes at lower doses. What SURMOUNT-5 adds that the separate trials could not is a controlled, same-population comparison. The difference in average weight loss observed here is more likely to reflect a true difference between the drugs than the cross-trial numbers alone could establish.

Both drugs share a recognizable side effect pattern. Gastrointestinal symptoms, including nausea, vomiting, diarrhea, and constipation, are the most commonly reported adverse events for both tirzepatide and semaglutide. These are most noticeable during dose escalation and often improve as the body adjusts. Whether one drug has a meaningfully better or worse tolerability profile than the other across all patients is not yet established. SURMOUNT-5 provides some comparative safety data within its study population, but broader long-term safety comparisons across different patient groups remain an area of ongoing research. What clinical experience does show is that individual tolerability varies. Some people stop one drug because of side effects and find the other more manageable. That variation is real, but it cannot be reliably predicted from trial averages.

The trial data, including the head-to-head comparison in SURMOUNT-5, shows that tirzepatide produced higher average weight loss than semaglutide. But population-level averages do not predict what will happen for any individual person. The numbers themselves illustrate this. In STEP 1, roughly half of participants on semaglutide lost 15% or more of their body weight. In SURMOUNT-1, more than half of participants on tirzepatide lost 20% or more. Both outcomes represent real, clinically meaningful weight loss for many people. The factors that might influence which drug a clinician considers for a given patient, including existing health conditions, prior medication history, individual tolerability, and metabolic profile, are not yet supported by robust predictive data. The trials tell us what happened on average; they do not yet tell us who will respond better to which drug. Long-term comparative data beyond the 68 to 72-week trial windows also remains limited. What happens to weight loss, weight regain, and health outcomes over years rather than months is still an open question for both drugs.

If you are considering either of these medications, or are already taking one, these topics are worth raising.

Indication and approval

Both drugs are approved for chronic weight management, but their approvals for type 2 diabetes differ. Your clinician can clarify which indication applies to your situation.

Your GI history

A history of significant gastrointestinal problems is relevant context when discussing which drug to start with and how to approach dose escalation.

Other health conditions

Conditions like type 2 diabetes or cardiovascular disease may make certain mechanisms more or less relevant to your care.

Defining success

Ask what outcome you are targeting together, how you will know if the medication is working, and at what point you would reassess. Clear benchmarks make it easier to evaluate progress.

Useful questions to bring

"What outcome are we targeting, and over what timeframe?"

"How will we know if this is working well enough?"

"What would be a reason to stop or switch?"

This article does not cover dosing guidance or switching protocols. Those decisions require clinical judgment based on your individual history and response.

Cross-trial comparisons are informative, not definitive. Comparing STEP 1 and SURMOUNT-1 results is useful context, but those trials were not designed to be compared with each other.

Head-to-head data exists but has a defined scope. SURMOUNT-5 provides a controlled comparison, but its findings apply specifically to adults with obesity without type 2 diabetes and at maximum approved doses.

Long-term outcomes are not established. The trials ran approximately 68 to 72 weeks. What happens beyond that window, for weight maintenance, health outcomes, or side effects, is not yet well characterized.

The GIP mechanism is not fully characterized. Tirzepatide's dual-receptor approach appears to contribute to its effect, but the precise role of GIP receptor activation in weight loss is still being studied.

Individual response cannot be predicted. No data currently supports identifying in advance which patients will respond better to one drug versus the other.

More data from longer trials and broader populations will clarify several of these questions over the coming years.